Hepatitis C and HIV in injecting drug users in Armenia, Colombia
DOI:
https://doi.org/10.20882/adicciones.749Keywords:
hepatitis C, HIV, heroin, epidemiologyAbstract
A constant and progressive increase in the availability of heroin in Colombia in recent decades and the intravenous use of this drug have established the need to prevent a possible epidemic of HIV and hepatitis C. This research determined the sero-prevalence of hepatitis C and HIV according to sociodemographic characteristics and risk behaviors in people who inject drugs in Armenia, Colombia. This is a cross-sectional study on 265 users captured through respondent-driven sampling after informed consent. Sero-prevalence of hepatitis C was 22.3 % [95% CI 12.3 % -23.5 %]; for HIV infection, it was 2.6 % [95% CI 0.4 to 6.0]; 67.5% reported injecting for more than two years, 35 % shared needles and syringes, and 12.4 % had used a condom during their last sexual intercourse. Users who did not purchase syringes in drugstores in the last six months are 2.7 times [95% CI 1.32 to 5.48] more likely to contract hepatitis C; daily injection frequency was higher in HIV- positive cases [OR 2.87; 95% CI 0.55 to 15.9] but nonsignificant. One fourth of respondents are infected with HIV or hepatitis C, either as a single infection or co-infection. This study identified risk practices such as sharing needles and low condom use in the last six months, worldwide documented and discussed risk factors. This research is a first step in the search for strategies to prevent the spread of HIV infection and hepatitis C in networks of injecting drug users.References
Ball, A. L., Rana, S., & Dehne, K. L. (1998). HIV prevention among injecting drug users: responses in developing and transitional countries. Public Health Reports, 113, 170-181.
Berbesi, D., Montoya, L., & Segura, A. (2012). Prevalencia de VIH y comportamientos de riesgo en UDI en Medellín y Pereira. Bogotá: Ministerio de Protección Social.
Berbesi, D., Segura, A., & Montoya, L. (2013). Cross-sectional study of HIV prevalence and the characteristics of injecting drug users in Colombia. Journal of Substance Use, 36, 27-31.
Berbesi-Fernandez, D., Montoya-Vélez L., & Segura-Cardona A. (2013). Uso del condón y conocimientos sobre prevención del VIH entre los inyectadores de drogas de dos ciudades colombianas. Adicciones, 25, 321-326.
Bravo, MJ., Mejia, IE., & Barrio, G. (2008). Encuestas de Comportamiento en Consumidores de Drogas Con Alto Riesgo (CODAR): Herramientas Básicas. Washington, D.C.: Organización Panamericana de la Salud
Clatts, M. C., Colón-López, V., Giang, L. M., & Goldsamt, L. A. (2010). Prevalence and incidence of HCV infection among Vietnam heroin users with recent onset of injection. Journal of Urban Health: Bulletin of the New York Academy of Medicine, 87, 278-291.
Des Jarlais, D. C., & Friedman, S. R. (1987). HIV infection among intravenous drug users: epidemiology and risk reduction. AIDS, 1, 67-76.
Des Jarlais, D. C., Pinkerton, S., Hagan, H., Guardino, V., Feelemyer, J., Cooper, H. & Uuskula, A. (2013). 30 Years on Selected Issues in the Prevention of HIV among Persons Who Inject Drugs. Advances in Preventive Medicine, 23, 1-10.
Garten, R. J., Lai, S., Zhang, J., Liu, W., Chen, J., Vlahov, D., & Yu, X. F. (2004). Rapid transmission of hepatitis C virus among young injecting heroin users in Southern China. International Journal of Epidemiology, 33, 182-188.
Gómez, A. P. (2013). Colombia: fuera del ojo del huracán, pero todavía cerca. Adicciones,, 25, 106-108.
Hagan, H., & Des Jarlais, D. C. (2000). HIV and HCV infection among injecting drug users. The Mount Sinai Journal of Medicine, 67, 423-428.
Hagan, H., Des Jarlais, D. C., Stern, R., Lelutiu-Weinberger, C., Scheinmann, R., Strauss, S., & Flom, P. L. (2007). HCV synthesis project: preliminary analyses of HCV prevalence in relation to age and duration of injection. The International Journal on Drug Policy, 18, 341-351.
Magiorkinis, G., Sypsa, V., Magiorkinis, E., Paraskevis, D., Katsoulidou, A., Belshaw, R., & Hatzakis, A. (2013). Integrating Phylodynamics and Epidemiology to Estimate Transmission Diversity in Viral Epidemics. PLoS Computational Biology, 9, 1-11.
Mejía, I. E., & Gómez, A. P. (2005). La inyección de drogas en Bogotá: una amenaza creciente. Adicciones, 17, 251-260.
Mendez Diz, A. M., Schwarz, P., & Camarotti, A. C. (2009). Prácticas sexuales en usuarios de drogas y riesgo de transmisión del VIH/sida. Rev. argent. sociol, 7, 150-163.
Ministerio de Salud y Protección Social. (2012). Informe mundial de avances en la lucha contra el Sida. Colombia 2012. Recuperado de http://www.unaids.org/en/dataanalysis/knowyourresponse/countryprogressreports/2012countries/
Oliveira, J. F., & Paiva, M. S. (2007). Vulnerabilidade de mulheres usuárias de drogas ao HIV/AIDS em uma perspectiva de gênero. Escola Anna Nery, 11, 625-631.
OMS. (2014.). Nota Descriptiva No. 64. Hepatitis C. Recuperado de http://www.who.int/mediacentre/factsheets/fs164/es/
OMS, UNODC, UNAIDS. (2012). Guides for countries to set targets for universal access to HIV prevention, treatment and care for injecting drug users. Recuperado de http://apps.who.int/iris/bitstream/10665/77969/1/9789241504379_eng.pdf
ONUSIDA. (2012). Datos fundamentales sobre el sida. Recuperado de http://search2.unaids.org/custom/search.asp
ONUSIDA. (2000). Guías sobre la vigilancia del VIH de segunda generacíon. Recuperado de http://cedoc.cies.edu.ni/general/2nd_Generation%20%28D%29/Surveillance%20Guidelines/2nd%20Generation%20Surveillance/2nd%20gen%20Spa.pdf
Osimani, M., Chiparelli H., & Latorre L. (2005). Seroprevalencia para los virus de la inmunodeficiencia humana, hepatitis B y C en usuarios de drogas inyectables. Uruguay, 2003. Revista Médica del Uruguay, 21. Recuperado de http://www.scielo.edu.uy/scielo.php?script=sci_arttextypid=S0303
Platt, L., Rhodes, T., Hickman, M., Mikhailova, L., Lisetsky, K., Sarang, A. & Parry, J. (2008). Changes in HIV prevalence and risk among new injecting drug users in a Russian city of high HIV prevalence. Journal of Acquired Immune Deficiency Syndromes, 47, 623-631.
Platt, L., Vickerman, P., Collumbien, M., Hasan, S., Lalji, N., Mayhew, S., & Hawkes, S. (2009). Prevalence of HIV, HCV and sexually transmitted infections among injecting drug users in Rawalpindi and Abbottabad, Pakistan: evidence for an emerging injection-related HIV epidemic. Sexually Transmitted Infections, 85, 17-22.
Ramirez-Valles, J., Heckathorn, D. D., Vázquez, R., Diaz, R. M., & Campbell, R. T. (2005). From networks to populations: the development and application of respondent-driven sampling among IDUs and Latino gay men. AIDS and Behavior, 9, 387-402.
Ruan, Y., Qin, G., Yin, L., Chen, K., Qian, H.-Z., Hao, C. & Shao, Y. (2007). Incidence of HIV, hepatitis C and hepatitis B viruses among injection drug users in southwestern China: a 3-year follow-up study. AIDS, 21, 39-46.
Shapatava, E., Nelson, K. E., Tsertsvadze, T., & del Rio, C. (2006). Risk behaviors and HIV, hepatitis B, and hepatitis C seroprevalence among injection drug users in Georgia. Drug and Alcohol Dependence, 82, S35-38.
Strathdee, S. A., Lozada, R., Pollini, R. A., Brouwer, K. C., Mantsios, A., Abramovitz, D. A., & Patterson, T. L. (2008). Individual, Social, and Environmental Influences Associated With HIV Infection Among Injection Drug Users in Tijuana, Mexico. Journal of Acquired Immune Deficiency Syndromes, 47, 369-376.
UNAIDS. (2012). Global Report. UNAIDS report on the global AIDS epidemic. Recuperado de http://www.unaids.org/
UNAIDS. (2014). Harm reduction works. Recuperado de http://www.unaids.org/es/resources/documents/2014/name,92033,es.asp
USAID. (2012). Uso de drogas y transmisión del VIH en America Latina. AIDSTAR-One. Recuperado de http://www.aidstar-one.com/sites/default/files/AIDSTAR-One_uso_de_drogas_y_transmision_del_VIH_en_america_latina.pdf
WHO, UNODC, UNAIDS. (2012). Technical guide for countries to set targets for universal access to HIV prevention, treatment and care for injecting drug users. Recuperado de http://www.who.int/hiv/pub/idu/targets_universal_access/en/
